We discovered that IGFBP-3 can bind bFGF, HGF, NRG, and PDGF as well as IGF1 and IGF2, engineered multiple constructs with improved drug properties which can inhibit the activities of these growth factors, and demonstrated improvement in efficacy when used in combination with numerous clinical standard of care cancer therapeutics in multiple tumor cell lines. Here, FGF2 is linked to cancer.